What is the prevalence of Congenital Sucrase Isomaltase Deficiency?

Congenital Sucrase-Isomaltase Deficiency (CSID) is a rare genetic disorder with an estimated prevalence ranging from 1 in 500 to 1 in 5,000 individuals, depending on the population studied. Because the condition is frequently misdiagnosed as Irritable Bowel Syndrome (IBS) or lactose intolerance, the true incidence remains difficult to determine with certainty.

How common is Congenital Sucrase-Isomaltase Deficiency?

Congenital Sucrase-Isomaltase Deficiency is classified as a rare disease. While global data is limited, prevalence estimates vary significantly by ethnic background. For example, in populations of Inuit descent, the frequency of Congenital Sucrase-Isomaltase Deficiency may be as high as 1 in 10 to 1 in 20. In North American and European populations, the prevalence is estimated to be much lower, often cited between 0.02% and 0.2%.

What factors influence the diagnosis of Congenital Sucrase-Isomaltase Deficiency?

The prevalence of Congenital Sucrase-Isomaltase Deficiency is likely higher than clinical data suggests due to several diagnostic challenges:

• Symptom overlap: Many patients with Congenital Sucrase-Isomaltase Deficiency are misdiagnosed with functional gastrointestinal disorders like IBS.


• Genetic variance: Symptoms often manifest when a child transitions from breast milk to solid foods, though milder cases may not be identified until adulthood.


• Diagnostic accessibility: Definitive diagnosis often requires a disaccharidase assay of a small bowel biopsy or specific genetic testing, which are not universally available.

Is there a gender or age bias in Congenital Sucrase-Isomaltase Deficiency?

Congenital Sucrase-Isomaltase Deficiency affects males and females equally, as it follows an autosomal recessive inheritance pattern. While it is a congenital condition, the age of onset can vary; symptoms typically begin in infancy, but individuals with partial enzyme activity may experience delayed onset, sometimes appearing only in late childhood or adulthood.

What does the patient community tell us?

Real-world data provides a vital lens through which we view Congenital Sucrase-Isomaltase Deficiency. Currently, 140 people with Congenital Sucrase-Isomaltase Deficiency have joined the DiseaseMaps.org community to share their personal experiences, highlighting that many patients endure years of gastrointestinal distress before receiving an accurate clinical diagnosis.

Next steps

• Consult a board-certified gastroenterologist or a metabolic specialist to discuss diagnostic testing.


• Request a referral for genetic counseling to understand the inheritance pattern of Congenital Sucrase-Isomaltase Deficiency.


• Connect with the 140 members of the DiseaseMaps.org community to share resources and coping strategies.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified physician regarding any medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Congenital sucrase-isomaltase deficiency.


• Orphanet (ORPHA: 835): Congenital sucrase-isomaltase deficiency.


• OMIM (Online Mendelian Inheritance in Man): Sucrase-Isomaltase Deficiency; CSID.